СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛЕКАРСТВЕННОЙ ТЕРАПИИ БОЛЬНЫХ РАКОМ ПОЧКИ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГА
https://doi.org/10.18027/2224-5057-2012-2-60-66
Аннотация
Об авторе
Д. Р. Насхлеташвили
ФГБУ «Российский онкологический научный центр имени Н.Н.Блохина» РАМН, Москва
Россия
Россия
Список литературы
1. Ammirati M, Cobbs CS, Linskey ME, et al. The role of retreatment in the management of recurrent/progressivebrain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010;96:85-96.
2. Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010; 16:269-278.
3. Choueiri TK, Duh MS, Clement J, et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2009;105:1247-1254.
4. Culine S, Bekradda M, Kramar A, et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83:2548-2553.
5. Dalhaung A, Haukland E, Nieder C. Leptomeningeal carcinomatosis from renal cell cancer: treatment attempt with radiation and sunitinib. World J Surg Oncol. 2010;8:36.
6. Elfiky AA, Cho DC, McDermott DF, et al. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear cell renal carcinoma. Urol Oncol. 2010; doi:10.1016/j.urolonc.2010.01.008; [Epub ahead of print].
7. Escudier B, Bellmut J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alpha-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28:2144-2150.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cell cancer global evaluation trial. J Clin Oncol. 2009;27:3312-3318.
9. Feldman DR, Baum MS, Ginsberg MS, et al. Phase 1 trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. Genitourinary Cancer. 2009;27:1432-1439.
10. Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renalcell carcinoma. New Engl J Med. 1998;338:1265-1271.
11. Gore ME, Hariharan S, Porta C, et al. Sunitinib in metastatic renal carcinoma patients with brain metastases. Cancer. 2011;117:501-509.
12. Guirgis LM, Yang JC, White DE, et al. Safety and efficacy of high dose IL-2 therapy in patients with brain metastasis. J Immunother. 2002;25:82-87.
13. Haznedar J, Patyna S, Bello CL, et al. Single and multiple dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2009;64:691-706.
14. Helgason HH, Mallo HA, Droogendijk H, et al. Brain metastases in patients with renal cell cancer new targeted treatment. J Clin Oncol. 2008;26:152-154.
15. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15:6062-69.
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal cell carcinoma. New Engl J Med.2007;456:2271-2281.
17. Iwamoto FM, Lamborn KR, Robins IH, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12:855-861.
18. Kim A, McCully C, Cruz R, et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates. Invest New Drugs. 2010; doi:10.1007/s10637-010-9585-1; [Epub ahead of print].
19. Kirchner H, Strumberg D, Bahl A, et al. Patient based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2010;10:585-596.
20. Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401-7406.
21. Lagas JS, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and p-glycoprotein limit sorafenib brain accumulation. Molec Cancer Ther. 2010;9:319-326.
22. Larkin J, Gore M. Is advanced renal cell carcinoma becoming a chronic disease? Lancet. 2010;376:574-575.
23. Lukas RV, Chmura S, Nicholas MK. Management of central nervous system metastases from renal cancer. Emerg Cancer Therap. 2011;2:157-168.
24. Massard C., Zonierek J., Gross-Goupil M., et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010;21:1027-31.
25. Medioni J, Cojocarasu O, Belcaceres JL, et al. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18:1282-1283.
26. Motzker RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal cell carcinoma. New Engl J Med. 2007;356:115-24.
27. Muacevic A, Siebels M, Tonn JC, et al. Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery? World JUrol. 2005;23:180-184.
28. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
29. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295-2305.
30. Murata JI, Sawamura Y, Terasaka S, et al. Complete response of a large brain metastasis of renal cell cancer to interferon-alpha: case report. Surg Neurol. 1999;51:289-291.
31. Nicholas MK, Lukas R. Immunologic privilege and the brain. In: Arnason BG, ed. NeuroImmune Biology: The Brain and Host Defense, Vol. 9. London, UK: Elsevier; 2010: 169-181.
32. O’Reilly T, McSheehy P, Kawai R, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol. 2010;54:625-639.
33. Saitoh H. Distant metastases from renal carcinoma. Cancer. 1988;48:1487-1491.
34. Samlowski WE, Majer M, Boucher KM, et al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008;113: 2539-2548.
35. Shuch B, LaRochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008; 113;1641-1648.
36. Shukla S, Robey RW, Bates SE, et al. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters p-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009;37:359-365.
37. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosisspecific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655-661.
38. Stadler WM, Figlin RA, McDermott DF, et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 2010;116:1272-1279.
39. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
40. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol. 2008; 86:243-244.
41. Ranze O, Hoffman E, Distelrath A, et al. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie. 2007;30:450-451.
42. Valcamonico F, Ferrari V, Amoroso V, et al. Long lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol. 2009;91:47-50.
43. Vogl UM, Bojic M, Lamm W, et al. Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. BMC Cancer. 2010;10:480.
44. Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15:1329-1334.
45. Yamanaka K, Gohji K, Hara I, et al. Clinical study of renal cell carcinoma with brain metastasis. Int J Urol. 1998;5:124-128.
46. Zeng H, Li X, Yao J, et al. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. Urol Int. 2009;83:482-485.
Рецензия
Для цитирования:
Насхлеташвили Д.Р. СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛЕКАРСТВЕННОЙ ТЕРАПИИ БОЛЬНЫХ РАКОМ ПОЧКИ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГА. Злокачественные опухоли. 2012;2(2):60-66. https://doi.org/10.18027/2224-5057-2012-2-60-66
Просмотров: 573
Послать статью по эл. почте 